Oxygen Biotherapeutics setting up for monster session after Phyxius deal

|By:, SA News Editor

Shares of Oxygen Biotherapeutics (OXBT) are building on Monday's AH gains, and are now up some 77% premarket.

After the bell Monday, the company outlined a major management shakeup and also announced the acquisition of levosimendan, a Phase 3 asset. 

More on the deal here